Distinct effects of methamphetamine on autophagy-lysosome and ubiquitin-proteasome systems in HL-1 cultured mouse atrial cardiomyocytes

Toxicology

Volumn 312, Issue 1, 2013, Pages 74-82

  Funakoshi Hirose, Izumi ^a   Aki, Toshihiko ^a   Unuma, Kana ^a   Funakoshi, Takeshi ^a   Noritake, Kanako ^a   Uemura, Koichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Autophagy; HL 1; Lysosome; Methamphetamine; Proteasome; Ubiquitin

Indexed keywords

ATROGIN 1; METHAMPHETAMINE; MUSCLE RING FINGER 1 PROTEIN; MYOSIN HEAVY CHAIN; PROTEASOME; PROTEIN P62; TRANSCRIPTION FACTOR NRF2; UBIQUITIN; UBIQUITINATED PROTEIN;

ANIMAL CELL; ARTICLE; AUTOLYSOSOME; AUTOPHAGOSOME; CARDIOTOXICITY; CELL VACUOLE; FLUORESCENCE MICROSCOPY; HEART MUSCLE CELL; IMMUNOPRECIPITATION; LYSOSOME MEMBRANE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REAL TIME POLYMERASE CHAIN REACTION; SARCOMERE; UBIQUITINATION; WESTERN BLOTTING;

ALS; AUTOPHAGY; AUTOPHAGY-LYSOSOME SYSTEM; GFP; GREEN FLUORESCENT PROTEIN; HEME OXYGENASE-1; HL-1; HO-1; LAMP1; LC3; LYSOSOME; LYSOSOME-ASSOCIATED MEMBRANE PROTEIN1; MAP; METHAMPHETAMINE; MHC; MICROTUBULES-ASSOCIATED PROTEIN LIGHT CHAIN3; MURF1; MUSCLE RING FINGER1; MYOSIN HEAVY CHAIN; NRF2; NUCLEAR FACTOR ERYTHROID-2 RELATED FACTOR; PROTEASOME; SNPP; TIN PROTOPORPHYRIN; UBIQUITIN; UBIQUITIN-PROTEASOME SYSTEM; UPS;

ANIMALS; AUTOPHAGY; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM STIMULANTS; HEME OXYGENASE-1; LYSOSOMES; METHAMPHETAMINE; MICE; MYOCYTES, CARDIAC; NF-E2-RELATED FACTOR 2; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84883263432     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.07.016     Document Type: Article

References (42)

1. Ago M., Ago K., Hara K., Kashimura S., Ogata M. Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: a case report. Leg. Med. (Tokyo) 2006, 8:235-239.
2. Aki T., Nara A., Uemura K. Cytoplasmic vacuolization during exposure to drugs and other substances. Cell Biol. Toxicol. 2012, 28:125-131.
3. Baird L., Dinkova-Kostova A.T. The cytoprotective role of the Keap1-Nrf2 pathway. Arch. Toxicol. 2011, 85:241-272.
4. Clarke B.A., Drujan D., Willis M.S., Murphy L.O., Corpina R.A., Burova E., Rakhilin S.V., Stitt T.N., Patterson C., Latres E., Glass D.J. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 2007, 6:376-385.
5. Claycomb W.C., Lanson N.A., Stallworth B.S., Egeland D.B., Delcarpio J.B., Bahinski A., Izzo N.J. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:2979-2984.
6. Cubells J.F., Rayport S., Rajendran G., Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 1994, 14:2260-2271.
7. Falcon-Perez J.M., Nazarian R., Sabatti C., Dell'Angelica E.C. Distribution and dynamics of Lamp1-containing endocytic organelles in fibroblasts deficient in BLOC-3. J. Cell Sci. 2005, 118:5243-5255.
8. Furukawa M., Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell. Biol. 2005, 25:162-171.
9. Huang Y.N., Wu C.H., Lin T.C., Wang J.Y. Methamphetamine induces heme oxygenase-1 expression in cortical neurons and glia to prevent its toxicity. Toxicol. Appl. Pharmacol. 2009, 240:315-326.
10. Islam M.N., Kuroki H., Hongcheng B., Ogura Y., Kawaguchi N., Onishi S., Wakasugi C. Cardiac lesions and their reversibility after long term administration of methamphetamine. Forensic. Sci. Int. 1995, 75:29-43.
11. Islam M.N., Jesmine K., Kong Sn Molh A., Hasnan J. Histopathological studies of cardiac lesions after long term administration of methamphetamine in high dosage-Part II. Leg. Med. (Tokyo) 2009, 11(Suppl. 1):S147-S150.
12. Kabeya Y., Mizushima N., Ueno T., Yamamoto A., Kirisako T., Noda T., Kominami E., Ohsumi Y., Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000, 19:5720-5728.
13. Kano F., Kondo H., Yamamoto A., Tanaka A.R., Hosokawa N., Nagata K., Murata M. The maintenance of the endoplasmic reticulum network is regulated by p47, a cofactor of p97, through phosphorylation by cdc2 kinase. Genes Cells 2005, 10:333-344.
14. Karch S.B. The unique histology of methamphetamine cardiomyopathy: a case report. Forensic. Sci. Int. 2011, 212:e1-e4.
15. Kaye S., McKetin R., Duflou J., Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007, 102:1204-1211.
16. Kedar V., McDonough H., Arya R., Li H.H., Rockman H.A., Patterson C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:18135-18140.
17. Komatsu M., Ichimura Y. Physiological significance of selective degradation of p62 by autophagy. FEBS Lett. 2010, 584:1374-1378.
18. Komatsu M., Waguri S., Koike M., Sou Y.S., Ueno T., Hara T., Mizushima N., Iwata J., Ezaki J., Murata S., Hamazaki J., Nishito Y., Iemura S., Natsume T., Yanagawa T., Uwayama J., Warabi E., Yoshida H., Ishii T., Kobayashi A., Yamamoto M., Yue Z., Uchiyama Y., Kominami E., Tanaka K. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007, 131:1149-1163.
19. Komatsu M., Kurokawa H., Waguri S., Taguchi K., Kobayashi A., Ichimura Y., Sou Y.S., Ueno I., Sakamoto A., Tong K.I., Kim M., Nishito Y., Iemura S., Natsume T., Ueno T., Kominami E., Motohashi H., Tanaka K., Yamamoto M. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat. Cell Biol. 2010, 12:213-223.
20. Komatsu M., Kageyama S., Ichimura Y. p62/SQSTM1/A170: physiology and pathology. Pharmacol. Res. 2012, 66:457-462.
21. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009, 60:379-407.
22. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
23. Lin M., Chandramani-Shivalingappa P., Jin H., Ghosh A., Anantharam V., Ali S., Kanthasamy A.G., Kanthasamy A. Methamphetamine-induced neurotoxicity linked to ubiquitin-proteasome system dysfunction and autophagy-related changes that can be modulated by protein kinase C delta in dopaminergic neuronal cells. Neuroscience 2012, 210:308-332.
24. Lokireddy S., Wijesoma I.W., Sze S.K., McFarlane C., Kambadur R., Sharma M. Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting. Am. J. Physiol. Cell Physiol. 2012, 303:C512-C529.
25. Mearini G., Gedicke C., Schlossarek S., Witt C.C., Kramer E., Cao P., Gomes M.D., Lecker S.H., Labeit S., Willis M.S., Eschenhagen T., Carrier L. Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc. Res. 2010, 85:357-366.
26. Moya-Huff F.A., Maher T.J. Adrenergic receptor subtype activation by (+)-, (-)- and (+/-)-norephedrine in the pithed rat. J. Pharm. Pharmacol. 1987, 39:108-112.
27. Nara A., Aki T., Funakoshi T., Uemura K. Methamphetamine induces macropinocytosis in differentiated SH-SY5Y human neuroblastoma cells. Brain Res. 2010, 1352:1-10.
28. Nara A., Aki T., Funakoshi T., Unuma K., Uemura K. Hyperstimulation of macropinocytosis leads to lysosomal dysfunction during exposure to methamphetamine in SH-SY5Y cells. Brain Res. 2012, 1466:1-14.
29. Nguyen T., Nioi P., Pickett C.B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 2009, 284:13291-13295.
30. Portbury A.L., Willis M.S., Patterson C. Tearin' up my heart: proteolysis in the cardiac sarcomere. J. Biol. Chem. 2011, 286:9929-9934.
31. Schindler C.W., Zheng J.W., Tella S.R., Goldberg S.R. Pharmacological mechanisms in the cardiovascular effects of methamphetamine in conscious squirrel monkeys. Pharmacol. Biochem. Behav. 1992, 42:791-796.
32. Sugimoto K., Okamura K., Tanaka H., Takashima S., Ochi H., Yamamoto T., Matoba R. Methamphetamine directly accelerates beating rate in cardiomyocytes by increasing Ca(2+) entry via L-type Ca(2+) channel. Biochem. Biophys. Res. Commun. 2009, 390:1214-1220.
33. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 2005, 75:406-433.
34. Tanaka Y., Guhde G., Suter A., Eskelinen E.L., Hartmann D., Lullmann-Rauch R., Janssen P.M., Blanz J., von Figura K., Saftig P. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000, 406:902-906.
35. Turdi S., Schamber R.M., Roe N.D., Chew H.G., Culver B., Ren J. Acute methamphetamine exposure inhibits cardiac contractile function. Toxicol. Lett. 2009, 189:152-158.
36. Uemura K., Aki T., Yamaguchi K., Yoshida K. Protein kinase C-epsilon protects PC12 cells against methamphetamine-induced death: possible involvement of suppression of glutamate receptor. Life Sci. 2003, 72:1595-1607.
37. Varner K.J., Ogden B.A., Delcarpio J., Meleg-Smith S. Cardiovascular responses elicited by the binge administration of methamphetamine. J. Pharmacol. Exp. Ther. 2002, 301:152-159.
38. Wang X., Robbins J. Heart failure and protein quality control. Circ. Res. 2006, 99:1315-1328.
39. White S.M., Constantin P.E., Claycomb W.C. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H823-H829.
40. Willis M.S., Schisler J.C., Portbury A.L., Patterson C. Build it up-tear it down: protein quality control in the cardiac sarcomere. Cardiovasc. Res. 2009, 81:439-448.
41. Yamaguchi O., Taneike M., Otsu K. Cooperation between proteolytic systems in cardiomyocyte recycling. Cardiovasc. Res. 2012, 96:46-52.
42. Yu Q., Larson D.F., Watson R.R. Heart disease, methamphetamine and AIDS. Life Sci. 2003, 73:129-140.